evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

290 questions · 295 findings · 24 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 73 · 24.7%GRADE not reported 23 · 7.8%Very low 55 · 18.6%Low 96 · 32.5%Moderate 37 · 12.5%High 11 · 3.7%

MSCs vs placebo or control

Death during study period · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

MSCs showed no clear difference in all‐cause mortality (prophylactic trials) (over duration of trial) compared with control/placebo (low certainty).

2 findings from 1 review

MSCs vs placebo or control

Relapse of malignant disease (prophylactic trials) (>12‐month · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

MSCs showed no clear difference in relapse of malignant disease (prophylactic trials) (>12‐month compared with control/placebo (low certainty).

1 finding from 1 review

MSCs vs placebo or control

Incidence of acute GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

MSCs showed no clear difference in incidence of acute GvHD (prophylactic trials) compared with control/placebo (low certainty).

1 finding from 1 review

MSCs vs placebo or control

Incidence of chronic GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

MSCs may leads to lower incidence of chronic GvHD (prophylactic trials) compared with control/placebo (low certainty).

1 finding from 1 review

MSCs vs placebo or control

Acute GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

It is very uncertain whether MSCs changes acute GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).

1 finding from 1 review

MSCs vs placebo or control

Chronic GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.

It is very uncertain whether MSCs changes chronic GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).

1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

All‐cause mortality up to 30 days № of participants: 72 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures

It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes all‐cause mortality up to 30 days № of participants: 72 (1 RCT) compared with no prophylactic plasma transfusion before surgery/invasive… (very low certainty).

1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Major bleeding · patients undergoing non‐cardiac surgery/invasive procedures

It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes major bleeding within 24 hours № of participants: 148 (2 RCTs) compared with no prophylactic plasma transfusion before surgery/invasive… (very low certainty).

1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Number of individuals requiring a transfusion within 7 days № of participants: 60 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures

It is very uncertain whether prophylactic plasma transfusion before surgery/invasive procedures changes number of individuals requiring a transfusion within 7 days № of… compared with no prophylactic plasma transfusion before surgery/invasive… (very low certainty).

1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures
1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment)

Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures

The review found no eligible studies for this question.

1 finding from 1 review